Skip to main content

Table 3 Mean comparison of prescriptions episodes (N=6,339)

From: Do newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications

 

Quantities prescribed (DDDs)

Intervals

Coverage ratio

Prescribed medications

   

 Generic Atorvastatin

20.04 ± 15.21***

38.77 ± 38.11***

0.64 ± 1.82**

 Originator Atorvastatin

29.80 ± 27.48

48.65 ± 40.00*

0.91 ± 3.47

 Other statins

30.59 ± 27.32

44.88 ± 44.19

0.79 ± 1.15

Previously treated

   

 Generic Atorvastatin

21.20 ± 15.65***

37.93 ± 31.99***

0.72 ± 2.57

 Originator Atorvastatin

32.84 ± 31.71

53.19 ± 39.80***

0.92 ± 4.13

 Other statins

27.17 ± 23.54

45.45 ± 50.05

0.74 ± 0.61

Newly treated

   

 Generic Atorvastatin

19.22 ± 14.83***

39.41 ± 42.21*

0.58 ± 0.89***

 Originator Atorvastatin

25.67 ± 19.66

41.76 ± 39.35

0.89 ± 2.13

 Other statins

27.17 ± 23.54

43.72 ± 51.37

0.91 ± 1.85

  1. Note: Data on other statins were used as the reference data in the statistical analysis
  2. *p < 0.5, **p < 0.001, ***p < 0.0001